CVS Health (CVS) FY2025 results: revenue $402.1 billion, up 7.8% on the year
CVS Health Corp. (CVS) reported revenue of $402.1 billion for fiscal 2025, the year ended 31 December 2025, up 7.8% on the year before. Net income was $1.8 billion, down 61.7%, and diluted earnings per share $1.39. The figures are the company's own, from the 10-K it filed with the SEC on 10 February 2026.
this yearthe year beforeHover a bar for its figure.
The year in brief
What management said about the year
Guidance figures: 1 lowered, 2 kept.
- Fourth-quarter revenue rose 8.2%: Revenue was $105.7 billion, against $97.7 billion a year earlier. GAAP diluted EPS was $2.30 versus $1.30, and Adjusted EPS was $1.09 versus $1.19.
- Adjusted EPS fell on Health Care Benefits: Management attributed the fourth-quarter Adjusted EPS decline to lower adjusted operating income in the Health Care Benefits segment.
- Full-year medical benefit ratio improved: The MBR was 91.2% for the year against 92.5%, and full-year adjusted operating income was $2.9 billion against $0.3 billion. Favorable prior-year development of $2.0 billion contributed.
- Goodwill impairment of $5.7 billion: Full-year operating income absorbed a $5.7 billion goodwill impairment on the Health Care Delivery unit within the Health Services segment. It is excluded from adjusted figures.
- Operating cash flow reached $10.6 billion: Full-year cash flow from operations was $10.6 billion against $9.1 billion in 2024.
From this 10-K
CVS Health is a health solutions company that connects insurance, pharmacy benefits management and retail pharmacy inside one group. At 31 December 2025 it had approximately 9,000 retail locations, more than 1,000 walk-in and primary care medical clinics and a pharmacy benefits manager with approximately 87 million plan members, and it served an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services. There are four reportable segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate/Other. The company states that its strategy is focused on simplifying health care experiences, improving engagement, lowering costs and delivering better health outcomes.
The four quarters: Q1 FY2025 · Q2 FY2025 · Q3 FY2025 · Q4 FY2025
Income statement (profit and loss)
| $ million | FY2025 | FY2024 | FY2023 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Revenue | 402,067 | 372,809 | 357,776 | +7.8% | |
| Cost of revenue | 221,167 | 206,287 | 217,098 | +7.2% | |
| Gross profit | 180,900 | 166,522 | 140,678 | +8.6% | |
| Gross margin | 45.0% | 44.7% | 39.3% | ||
| Operating income | 4,660 | 8,516 | 13,743 | -45.3% | |
| Operating margin | 1.2% | 2.3% | 3.8% | ||
| Interest expense | 3,119 | 2,958 | 2,658 | +5.4% | |
| Pre-tax income | 2,136 | 6,148 | 11,173 | -65.3% | |
| Income tax | 408 | 1,562 | 2,805 | -73.9% | |
| Effective tax rate | 19.1% | 25.4% | 25.1% | ||
| Net income | 1,768 | 4,614 | 8,344 | -61.7% | |
| Net margin | 0.4% | 1.2% | 2.3% | ||
| Diluted EPS | $1.39 | $3.66 | $6.47 | -62.0% |
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.Cash flow
| $ million | FY2025 | FY2024 | FY2023 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Operating cash flow | 10,639 | 9,107 | 13,426 | +16.8% | |
| Capital expenditure | 2,832 | 2,781 | 3,031 | +1.8% | |
| Free cash flow | 7,807 | 6,326 | 10,395 | +23.4% | |
| Free cash flow margin | 1.9% | 1.7% | 2.9% | ||
| Cash from investing | -5,871 | -7,613 | -20,889 | ||
| Cash from financing | -4,940 | -1,135 | 2,683 | ||
| Depreciation and amortisation | 4,606 | 4,597 | 4,366 | +0.2% | |
| Share-based compensation | 535 | 540 | 588 | -0.9% | |
| Buybacks | 0.0 | 3,023 | 2,012 | ||
| Dividends paid | 3,397 | 3,373 | 3,132 | +0.7% | |
| Dividend per share | $2.66 | $2.66 | $2.42 | 0.0% | |
| Diluted shares, weighted | 1,271m | 1,262m | 1,290m | +0.7% | |
| Shares outstanding at period end | 1,271m | 1,260m | 1,288m | +0.9% |
Balance sheet
| $ million | FY2025 | FY2024 | FY2023 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Shareholders' equity | 75,214 | 75,560 | 76,461 | -0.5% | |
| Non-controlling interest | 168 | 170 | 175 | -1.2% | |
| Debt | 64,570 | 66,270 | 61,610 | -2.6% | |
| Operating lease liabilities | 13,643 | 14,899 | 16,034 | -8.4% | |
| Finance lease liabilities | 1,265 | 1,295 | 1,325 | -2.3% | |
| Other liabilities | 98,678 | 95,021 | 94,123 | +3.8% | |
| Total liabilities and equity | 253,538 | 253,215 | 249,728 | +0.1% | |
| Goodwill | 85,478 | 91,272 | 91,272 | -6.3% | |
| Intangible assets | 25,508 | 27,323 | 29,234 | -6.6% | |
| Investments | 34,814 | 31,341 | 26,278 | +11.1% | |
| Cash and equivalents | 8,453 | 8,586 | 8,196 | -1.5% | |
| Receivables | 39,779 | 36,469 | 35,227 | +9.1% | |
| Inventory | 19,246 | 18,107 | 18,025 | +6.3% | |
| Other assets | 40,260 | 40,117 | 41,496 | +0.4% | |
| Total assets | 253,538 | 253,215 | 249,728 | +0.1% |
10-K for the year ended 31 December 2025, filed 10 February 2026: the filing.